Global Induced Pluripotent Stem Cells (iPSCs) Market - Industry Trends and Forecast to 2029

TABLE OF CONTENT

TABLE OF CONTENTS
1 INTRODUCTION 34
1.1 OBJECTIVES OF THE STUDY 34
1.2 MARKET DEFINITION 34
1.3 OVERVIEW OF GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET 34
1.4 LIMITATIONS 36
1.5 MARKETS COVERED 36
2 MARKET SEGMENTATION 38
2.1 MARKETS COVERED 38
2.2 GEOGRAPHICAL SCOPE 39
2.3 YEARS CONSIDERED FOR THE STUDY 40
2.4 CURRENCY AND PRICING 40
2.5 DBMR TRIPOD DATA VALIDATION MODEL 41
2.6 MULTIVARIATE MODELLING 44
2.7 CELL SOURCE LIFELINE CURVE 44
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 45
2.9 DBMR MARKET POSITION GRID 46
2.10 MARKET APPLICATION COVERAGE GRID 47
2.11 VENDOR SHARE ANALYSIS 48
2.12 SECONDARY SOURCES 49
2.13 ASSUMPTIONS 49
3 EXECUTIVE SUMMARY 50
4 PREMIUM INSIGHTS 53
5 GLOBAL MEDICAL CARTS MARKET: REGULATIONS 56
5.1 REGULATION IN U.S. 56
5.2 REGULATION IN CANADA 57
5.3 REGULATION IN EUROPE 57
5.4 REGULATION IN INDIA 57
5.5 REGUALTION IN JAPAN 58
6 MARKET OVERVIEW 60
6.1 DRIVERS 62
6.1.1 WIDE RANGE OF CLINICAL APPLICATION OF INDUCED PLURIPOTENT STEM CELLS 62
6.1.2 EMERGING TECHNOLOGICAL ADVANTAGES OF IPSCS 62
6.1.3 RISING PREVALENCE OF SEVERAL CHRONIC DISEASES 63
6.1.4 INCREASING ADOPTION OF STEM CELL THERAPY 65
6.1.5 GROWING BIOTECHNOLOGY SECTOR WITH BETTER INVESTMENT 66
6.2 RESTRAINT 67
6.2.1 HIGH COST ASSOCIATED WITH STEM CELL THERAPIES AND LARGE-SCALE APPLICATIONS OF IPSCS 67
6.2.2 AVAILABILITY OF ALTERNATIVES FOR TUMOR TREATMENT 67
6.2.3 ADVERSE EFFECTS OF STEM CELL TRANSPLANTS 68
6.3 OPPORTUNITIES 68
6.3.1 INCREASING NUMBER OF PIPELINE PRODUCTS 68
6.3.2 INCREASING INTEREST OF PERSONALIZED MEDICINE 69
6.3.3 SURGE IN HEALTHCARE EXPENDITURE 69
6.3.4 STRATEGIC INITIATIVES BY KEY MARKET PLAYERS 70
6.4 CHALLENGES 71
6.4.1 GENOMIC INSTABILITY OF IPSCS IS THE KEY MARKET CHALLENGE 71
6.4.2 LACK OF SKILLED PROFESSIONALS 71
6.4.3 STRINGENT REGULATORY FRAMEWORK 71
7 IMPACT OF COVID-19 ON THE GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET 73
7.1 IMPACT ON PRICE 73
7.2 IMPACT ON DEMAND 73
7.3 IMPACT ON SUPPLY CHAIN 74
7.4 STRATEGIC DECISIONS BY MANUFACTURERS 74
7.5 CONCLUSION 75
8 GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY CELL SOURCE 76
8.1 OVERVIEW 77
8.2 SKIN CELLS 79
8.2.1 FIBROBLAST 80
8.2.2 KERATINOCYTES 80
8.2.3 ADIPOSE DERIVED STEM CELLS 81
8.2.4 HEPATOCYTES 81
8.2.5 MELANOCYTES 81
8.2.6 NEURAL STEM CELLS 81
8.2.7 OTHERS 81
8.3 BLOOD CELLS 81
8.3.1 PERIPHERAL BLOOD 82
8.3.2 CORD BLOOD ENDOTHELIAL CELLS 82
8.3.3 CORD BLOOD STEM CELLS 82
8.3.4 OTHERS 82
9 GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY TYPE 83
9.1 OVERVIEW 84
9.2 HUMAN IPSCS 87
9.3 MOUSE IPSCS 87
10 GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY PRODUCT 89
10.1 OVERVIEW 90
10.2 CONSUMABLES & KITS 93
10.2.1 REPROGRAMMING KITS 94
10.2.2 MEDIA 94
10.2.3 TRANSFECTION KITS 94
10.2.4 CELL IDENTIFICATION KITS 94
10.2.5 ACCESSORIES 94
10.2.6 OTHERS 94
10.3 SERVICES 94
10.4 INSTRUMENTS 95
10.4.1 IMAGING SYSTEMS 96
10.4.2 ELECTROPORATION DEVICE 96
10.4.3 INCUBATORS 96
10.4.4 OTHERS 96
11 GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY APPLICATION 97
11.1 OVERVIEW 98
11.2 DRUG DISCOVERY AND DEVELOPMENT 101
11.3 ACADEMIC RESEARCH 101
11.4 DISEASE MODELLING 102
11.5 CELLULAR THERAPY 103
11.6 REGENERATIVE MEDICINE 103
11.7 TOXICOLOGY SCREENING 104
11.8 STEM CELL BANKING 105
11.9 3D BIOPRINTING 105
11.10 OTHERS 106
12 GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY END USER 107
12.1 OVERVIEW 108
12.2 BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES 111
12.3 RESEARCH LABORATORIES 111
12.4 DIAGNOSTIC LABORATORIES 112
12.5 OTHERS 113
13 GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY DISTRIBUTION CHANNEL 114
13.1 OVERVIEW 115
13.2 DIRECT TENDER 117
13.3 RETAIL SALES 118
14 GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET, BY REGION 119
14.1 OVERVIEW 120
14.2 NORTH AMERICA 125
14.2.1 U.S. 132
14.2.2 CANADA 135
14.2.3 MEXICO 138
14.3 EUROPE 141
14.3.1 GERMANY 148
14.3.2 FRANCE 151
14.3.3 U.K. 154
14.3.4 ITALY 157
14.3.5 RUSSIA 160
14.3.6 SPAIN 163
14.3.7 TURKEY 166
14.3.8 NETHERLANDS 169
14.3.9 SWITZERLAND 172
14.3.10 BELGIUM 175
14.3.11 REST OF EUROPE 178
14.4 ASIA-PACIFIC 179
14.4.1 CHINA 188
14.4.2 JAPAN 191
14.4.3 INDIA 194
14.4.4 SOUTH KOREA 197
14.4.5 AUSTRALIA 200
14.4.6 SINGAPORE 203
14.4.7 THAILAND 206
14.4.8 MALAYSIA 209
14.4.9 INDONESIA 212
14.4.10 PHILIPPINES 215
14.4.11 REST OF ASIA-PACIFIC 218
14.5 SOUTH AMERICA 219
14.5.1 BRAZIL 226
14.5.2 ARGENTINA 229
14.5.3 REST OF SOUTH AMERICA 232
14.6 MIDDLE EAST AND AFRICA 233
14.6.1 SOUTH AFRICA 240
14.6.2 SAUDI ARABIA 243
14.6.3 UAE 246
14.6.4 EGYPT 249
14.6.5 ISRAEL 252
14.6.6 REST OF MIDDLE EAST AND AFRICA 255
15 GLOBAL INDUCED PLURIPOTENT STEM CELLS (IPSCS) MARKET: COMPANY LANDSCAPE 256
15.1 COMPANY SHARE ANALYSIS: GLOBAL 256
15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 257
15.3 COMPANY SHARE ANALYSIS: EUROPE 258
15.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 259
16 SWOT ANALYSIS 260
17 COMPANY PROFILE 261
17.1 FUJIFILM CORPORATION 261
17.1.1 COMPANY SNAPSHOT 261
17.1.2 REVENUE ANALYSIS 261
17.1.3 COMPANY SHARE ANALYSIS 262
17.1.4 PRODUCT PORTFOLIO 262
17.1.5 RECENT DEVELOPMENT 263
17.1.5.1 ACQUISITION 263
17.2 THERMO FISHER SCIENTIFIC INC. 264
17.2.1 COMPANY SNAPSHOT 264
17.2.2 REVENUE ANALYSIS 264
17.2.3 COMPANY SHARE ANALYSIS 265
17.2.4 PRODUCT PORTFOLIO 265
17.2.5 RECENT DEVELOPMENTS 268
17.2.5.1 EVENT 268
17.2.5.2 ACQUISITION 269
17.3 LONZA. 270
17.3.1 COMPANY SNAPSHOT 270
17.3.2 REVENUE ANALYSIS 270
17.3.3 COMPANY SHARE ANALYSIS 271
17.3.4 PRODUCT PORTFOLIO 271
17.3.5 RECENT DEVELOPMENTS 272
17.3.5.1 EXPANSION 272

17.4 MERCK KGAA 273
17.4.1 COMPANY SNAPSHOT 273
17.4.2 REVENUE ANALYSIS 273
17.4.3 COMPANY SHARE ANALYSIS 274
17.4.4 PRODUCT PORTFOLIO 274
17.4.5 RECENT DEVELOPMENT 277
17.4.5.1 AGREEMENT 277
17.5 EVOTEC SE. 278
17.5.1 COMPANY SNAPSHOT 278
17.5.2 REVENUE ANALYSIS 278
17.5.3 COMPANY SHARE ANALYSIS 279
17.5.4 PRODUCT PORTFOLIO 279
17.5.5 RECENT DEVELOPMENTS 279
17.5.5.1 AGREEMENT 279
17.5.5.2 COLLABORATION 280
17.6 APPLIED STEMCELL. 281
17.6.1 COMPANY SNAPSHOT 281
17.6.2 PRODUCT PORTFOLIO 281
17.6.3 RECENT DEVELOPMENTS 287
17.6.3.1 PRODUCT LAUNCH 287
17.7 AXOL BIOSCIENCE LTD. 288
17.7.1 COMPANY SNAPSHOT 288
17.7.2 PRODUCT PORTFOLIO 288
17.7.3 RECENT DEVELOPMENTS 291
17.7.3.1 MERGER 291
17.7.3.2 PRODUCT LAUNCH 292
17.8 CELL APPLICATIONS, INC. 293
17.8.1 COMPANY SNAPSHOT 293
17.8.2 PRODUCT PORTFOLIO 293
17.8.3 RECENT DEVELOPMENT 294
17.8.3.1 PARTNERSHIP 294
17.9 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 295
17.9.1 COMPANY SNAPSHOT 295
17.9.2 REVENUE ANALYSIS 295
17.9.3 PRODUCT PORTFOLIO 296
17.9.4 RECENT DEVELOPMENT 296
17.9.4.1 ACQUISITION 296

17.10 CITIUS PHARMACEUTICALS, INC. 297
17.10.1 COMPANY SNAPSHOT 297
17.10.2 PRODUCT PORTFOLIO 297
17.10.3 RECENT DEVELOPMENT 297
17.10.3.1 AGREEMENT 297
17.11 CORNING INCORPORATED 298
17.11.1 COMPANY SNAPSHOT 298
17.11.2 REVENUE ANALYSIS 298
17.11.3 PRODUCT PORTFOLIO 299
17.11.4 RECENT DEVELOPMENT 299
17.11.4.1 AGREEMENT 299
17.12 FATE THERAPEUTICS 300
17.12.1 COMPANY SNAPSHOT 300
17.12.2 PRODUCT PORTFOLIO 300
17.12.3 RECENT DEVELOPMENT 300
17.12.3.1 CLINICAL TRIAL 300
17.13 GENECOPOEIA, INC. 301
17.13.1 COMPANY SNAPSHOT 301
17.13.2 PRODUCT PORTFOLIO 301
17.13.3 RECENT DEVELOPMENT 301
17.14 HOPSTEM BIOTECHNOLOGY LLC. 302
17.14.1 COMPANY SNAPSHOT 302
17.14.2 PRODUCT PORTFOLIO 302
17.14.3 RECENT DEVELOPMENT 302
17.14.3.1 PARTNERSHIP 302
17.15 HORIZON DISCOVERY LTD. 303
17.15.1 COMPANY SNAPSHOT 303
17.15.2 PRODUCT PORTFOLIO 303
17.15.3 RECENT DEVELOPMENT 303
17.16 LUMACYTE 304
17.16.1 COMPANY SNAPSHOT 304
17.16.2 PRODUCT PORTFOLIO 304
17.16.3 RECENT DEVELOPMENT 305
17.16.3.1 COLLABORATION 305
17.17 R & D SYSTEMS, INC. 306
17.17.1 COMPANY SNAPSHOT 306
17.17.2 REVENUE ANALYSIS 306
17.17.3 PRODUCT PORTFOLIO 307
17.17.4 RECENT DEVELOPMENT 308

17.18 REPROCELL INC. 309
17.18.1 COMPANY SNAPSHOT 309
17.18.2 PRODUCT PORTFOLIO 309
17.18.3 RECENT DEVELOPMENTS 310
17.18.3.1 COLLABORATION 310
17.18.3.2 FACILITY EXPANSION 311
17.18.3.3 SERVICE LAUNCH 311
17.19 TAKARA BIO INC. 312
17.19.1 COMPANY SNAPSHOT 312
17.19.2 REVENUE ANALYSIS 312
17.19.3 PRODUCT PORTFOLIO 313
17.19.4 RECENT DEVELOPMENTS 313
17.19.4.1 NEW FACILITY LAUNCH 313
17.20 UNIVERSAL CELLS INC. (AN ASTELLAS COMPANY) 314
17.20.1 COMPANY SNAPSHOT 314
17.20.2 REVENUE ANALYSIS 314
17.20.3 PRODUCT PORTFOLIO 315
17.20.4 RECENT DEVELOPMENT 315
17.20.4.1 ACQUISITION 315
18 QUESTIONNAIRE 316
19 RELATED REPORTS 320